Publication of prospectus regarding rights issue in SAS
As previously announced, SAS AB (”SAS”) has resolved to conduct a rights issue of approximately SEK 5 billion.
The Board of Directors of SAS has prepared a prospectus regarding the rights issue and the listing of the new shares on NASDAQ OMX Stockholm, NASDAQ OMX Copenhagen and Oslo Børs, which has been approved and registered by the Swedish Financial Supervisory Authority. The prospectus is available on SAS’ website, www.sasgroup.net under Investor Relations, on the website of Nordea, www.nordea.se/placera, and on the website of SEB, www.seb.se/prospekt. The prospectus is also available, free of charge, at the headquarters of SAS (Frösundaviks Allé 1, Solna) and can, to the extent permissible under applicable securities regulations, be ordered from Nordea by telephone +46 8 678 04 50 (Sweden), +45 33 33 50 92 (Denmark) and +47 22 48 62 62 (Norway).
A Swedish or English version of the prospectus, and/or an information brochure in Swedish, Danish and Norwegian, respectively, will be distributed beginning on or around 14 April 2010 to shareholders who are directly registered in Euroclear Sweden (former VPC), Danish VP Securities or Norwegian Verdipapirsentralen. The information brochure in Swedish, Danish and Norwegian is also available on the website of SAS, www.sasgroup.net under Investor Relations. Shareholders with nominee registered shares should contact the relevant nominee for further information and instructions.
For further information, please contact
Nordea Customer Service in
Sweden: +46 678 04 50;
Denmark: +45 33 33 50 92; or
Norway: +47 22 48 62 62.
Sture Stølen, Head of SAS Group Investor Relations, +46 70 997 1451
SAS discloses this information pursuant to the Swedish Securities Market Act and/or the Swedish Financial Instruments Trading Act. The information was provided for publication on 9 April 2010 at 16:00 CET.
This document is not being distributed to persons in any state or jurisdiction where the offer or sale of the rights or shares is not permitted.
These materials are not an offer for sale of securities in the United States. Securities may not be sold in the United States absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended. The issuer of the securities does not intend to register any part of the offering in the United States or to conduct a public offering of the Rights or the Shares in the United States.
This document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons in (i), (ii) and (iii) above together being referred to as “relevant persons”). The Rights and the Shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.
This document is an advertisement and is not a prospectus for the purposes of Directive 2003/71/EC (such Directive, together with any applicable implementing measures in the relevant home Member State under such Directive, the “Prospectus Directive”). A prospectus prepared pursuant to the Prospectus Directive will be published, which, when published, can be obtained from the SAS Group. Investors should not subscribe for any securities referred to in this document except on the basis of information contained in the prospectus.
In any EEA Member State that has implemented the Prospective Directive, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive.